• 1. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet1969; 2: 1380-2.
  • 2. Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303: 893-6
  • 3. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12.
  • 4. WHO. Human Genetic Program.Familial Hypercholesterolemia.Report of a WHO consultation. WHO/HGN/FH/CONS/98.7 Paris; October 1997.
  • 5. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK Phenotypic variation in heterozygous familial Hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. ArteriosclerThrombVascBiol 1998; 18: 309-15.
  • 6. Goldstein, JL, Hobbs HH, Brown MS. Familial Hypercholesterolemia.In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease, vol II New York: McGraw Hill. 2001:2863-2913.
  • 7. Villeger L, Abifadel M, Allard D, Rabès JP, Thiart R, Kotze MJ et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum Mutat 2002; 20: 81-7
  • 8. Castillo S, Tejedor D, Mozas P, Reyes G, Civeira F, Alonso R et al. The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 2002;165:127-35.
  • 9. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH et al The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256: 482-90.
  • 10. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA.A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.ArteriosclerThrombVasc Biol. 2007;27:1803-10.
  • 11. van der GraafA, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am CollCardiol. 2008 Oct 21;52(17):1421-9.
  • 12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625–33.
  • 13. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH etal.Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
  • 14. Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008; 200: 315-21.
  • 15. Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. ClinBiochem 2009; 42:899-903.
  • 16. Miname M, Riberiro M, PargaFilho J et al. Evaluation of subclinical aterosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 2010;213:486-91.
  • 17. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208:317-21.
  • 18. Nherera L, Marks D, Thorogood M, Humprhries S. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97:1175-81.

Los comentarios están cerrados.